Keyphrases
Radiotherapy
100%
Promoter Methylation
100%
Methylation
100%
Glioblastoma
100%
Temozolomide
100%
Methylguanine Methyltransferase
100%
Overall Survival
37%
Pyrosequencing
25%
CpG Sites
25%
Progression-free Survival
25%
2-year Survival
25%
Improved Survival
12%
Long-term Survival
12%
Chemoradiotherapy
12%
Clinical Samples
12%
Treatment Facilities
12%
Quantitative Methylation
12%
Methylation Status
12%
Epigenetic Silencing
12%
Multiple Samples
12%
Survival Median
12%
Median Progression-free Survival
12%
Median Overall Survival
12%
Methylation Data
12%
Independent Prognostic Factor
12%
Archival Samples
12%
Non-neoplastic
12%
Prognostic Stratification
12%
Alkylating Agents
12%
Methylation Pattern
12%
O6-methylguanine-DNA Methyltransferase
12%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Glioblastoma
100%
DNA Methyltransferase
100%
Overall Survival
57%
Progression Free Survival
42%
Chemoradiation Therapy
14%
6 O Methylguanine
14%
Alkylating Agent
14%
Biochemistry, Genetics and Molecular Biology
Methylation
100%
Promoter Region
100%
DNA Methyltransferase
100%
Overall Survival
28%
Progression Free Survival
21%
CpG Site
14%
Pyrosequencing
14%
Epigenetics
7%
O-6-Methylguanine-DNA Methyltransferase
7%
Veterinary Science and Veterinary Medicine
Temozolomide
100%
Non-Neoplastic
50%
Protocerebrum
50%
Neuroscience
Alkylating Antineoplastic Agent
7%